2012.01.05 Weekly Broadcast Email
There following updates were made to the CCCWFU CCOP Research Base website for the week of January 2, 2012.
91105 (Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients)
Closure announcement from study PI:
Enrollment is now closed for 91105. Please send in participants MRIs and reimbursement requests. Thanks to all for making this study an enrollment success!!
Steve Rapp, PhD, PI
The following adverse event was received during the month of December. It has been attached to this email and summarized on the Adverse Event webpage.
During the month of December, 25 patients were accrued to CCCWFU CCOP Research Base trials. Congratulations to the Iowa CCOP for accruing the most patients. See the Research Base website spotlight section for further information.
98110 (ArginMax for Prostate Cancer Survivors Treated with Radiotherapy)
Announcement from study PI:
As a reminder, our dose finding study of ArginMax for prostate cancer survivors treated with radiotherapy remains open for accrual. To date, we have accrued 70 + patients of a planned 140 averaging nearly 6 patients per month. We appreciate the robust accrual to date and overall support of this study. During the past month, we have noticed a slight dip in accrual. We encourage all sites to continue either their excellent accrual or consider opening this study. With your continued robust support, we are likely to finish this study in about 1 more year. If there are questions regarding accrual please do not hesitate to contact me or the study team.
James J. Urbanic, M.D.